Net income
−$7.1M
−267.8% vs same quarter last year
EPS, diluted
−$2.17
+0.9% vs same quarter last year
Operating cash flow
−$5.3M
−189.1% vs same quarter last year
Operating income
−$6.4M
−282.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$8.9M |
| FY24 | $780K | −$5.7M |
| FY23 | $1.2M | −$8.2M |
| FY22 | $1.8M | −$10.1M |
| FY21 | $1.3M | −$8.5M |
| FY20 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | 0.3% | −573.8% | −725% |
| FY23 | 24.4% | −701.1% | −701% |
| FY22 | 16.2% | −548.8% | −548.7% |
| FY21 | −3% | −448.1% | −675.7% |
| FY20 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$7M |
| FY24 | −$5.7M |
| FY23 | −$8.6M |
| FY22 | −$8.9M |
| FY21 | - |
| FY20 | - |
- Valion Bio
- Healthcare median
Show the numbers
| Year | Valion Bio | Healthcare median |
|---|---|---|
| FY25 | - | −66.4% |
| FY24 | −725% | −87% |
| FY23 | −701% | −128.5% |
| FY22 | −548.7% | −143.6% |
| FY21 | −675.7% | −137.7% |
| FY20 | - | −134.3% |
News
No stories filed under Valion Bio yet - coverage appears here as the news feed clusters it.